The capture of Nicolás Maduro will force officials in Tehran to consider a broader range of risks as Trump threatens to ...

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

The company was aiming for approval in the second half of 2028, paving the way for a market launch in 2029 Hangzhou-based ...

I’ve been the doctor responding to medical emergencies on a flight, and the medical kits I used contained minimal supplies.

Seattle biotech startup Rhizome Research has emerged from stealth with technology for creating small-molecule drug candidates ...

Maduro’s capture is not really about drugs. It is about power, oil, ideology, distraction and the cost of mistaking stability ...

Large language models are powering a new generation of AI agents that could transform computational chemistry from a ...

ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...

S. Korea will raise its median income standard by 6.5% this year, the largest increase on record, expanding eligibility for ...

When we see a declining return on capital employed (ROCE) in conjunction with a declining base of capital employed, that's often how a mature business shows signs of aging. This combination can tell ...

A competitor's setback was Xeris Biopharma's (NASDAQ: XERS) gain on Hump Day. On news that a potential commercial threat to ...

The reluctance of the top 1% to use their vast resources to protect democracy has left many of us feeling powerless, even ...